At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
Camostat Mesilate +1 moredrug
Likely dose
Camostat Mesilate 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial
In Brief
A Phase 2 clinical trial evaluating Camostat Mesilate and Placebo for COVID-19. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The rationale of the present clinical trial is that an orally available drug given to outpatients that could reduce the viral burden in the upper respiratory tract could forestall complications of SARS-CoV-2 infection and reduce transmission from one infected individual to another.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJun 2020
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedApr 20, 2020
Enrollment StartJun 9, 2020
Primary CompletionMar 3, 2021
Study CompletionApr 22, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.2 years ago
Interventions
Camostat Mesilatedrug
Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
Placeboother
Placebo taken orally, 4 times daily, for 7 days.